It’s not too convincing to stay loyal to Cronos Group (TSX:CRON)(NASDAQ:CRON) stock after seeing its fourth-quarter earnings report. The marijuana producer has delivered sales much lower than market expectations, raising questions about its rich valuations.
In a report released on March 26, Cronos reported that sales for the quarter, the first full period after Canada legalized recreational consumption, were $5.6 million, missing analysts’ expectations of more than $10 million.
The sales number also showed that Cronos, in which tobacco giant Altria Group has $2.4 billion strategic investment, was behind than its competitors in capturing the share of recreational pot market in Canada.
For example, Canopy Growth and Aurora Cannabis had quarterly revenues of $83 million and $54 million, respectively, while Hexo posted revenues of $13 million.
Long-term value creation
From the management’s perspective, this performance shouldn’t cause worry for investors. CEO Mike Gorenstein said the company has taken a different route to create long-term value for investors.
It’s investing in areas of the marijuana supply chain, such as developing branded products and intellectual property, rather than cultivation and production capacity.
“This focused approach is proving successful and analogous industries, such as consumer packaged goods in pharmaceuticals, and we think it will prove successful in the cannabis industry as well,” he told analysts on a conference call as cited by Reuters. “In other words, you can expect our focus to be on making the cheese, rather than raising and milking the cows.”
That response still didn’t satisfy some analysts who cut the Cronos’s price target. Canaccord Genuity analyst Matt Bottomley, who lowered his rating for Cronos after the Q4 results, said earnings pointed to a soft start. “As we believe CRON’s valuation was somewhat stretched at Altria’s investment price of $16.25, we are lowering our recommendation primarily on valuation,” he said in a note.
Hurt by these negative sentiment, CRON stock has seen a major sell-off, extending its past-month decline to 23% at the time of writing. Despite this plunge, Cronos stock, trading at $24.39, is still up 70% this year, showing that investors believe in the company’s long-term growth story.
With so little data available about the top marijuana companies’ past performance and growth potential, it doesn’t seem a right approach to punish CRON stock after its first full quarter report.
Any weakness in its stock may offer a good buying opportunity for long-term investors, especially when the company is backed by Altria Group, which has deep pockets and expertise to help this weed producer grow.
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Haris Anwar has no position in the stocks mentioned in this article.